(Q31919646)

5 July 2017

Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas (English)

1 reference

5 July 2017

0 references

1 reference

Silvestre RA

1

1 reference

5 July 2017

Rodríguez-Gallardo J

2

1 reference

5 July 2017

Jodka C

3

1 reference

5 July 2017

Parkes DG

4

1 reference

5 July 2017

Pittner RA

5

1 reference

5 July 2017

Young AA

6

1 reference

5 July 2017

Marco J

7

1 reference

5 July 2017

1 March 2001

1 reference

American Journal of Physiology - Endocrinology and Metabolism

5 July 2017

1 reference

5 July 2017

280

1 reference

5 July 2017

3

1 reference

5 July 2017

E443-9

1 reference

Normalization of fasting hyperglucagonemia and excessive glucagon responses to intravenous arginine in human diabetes mellitus by prolonged infusion of insulin

5 July 2017

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.3.E443

Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.3.E443

Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.3.E443

Somatostatin, insulin and glucagon secretion by the perfused pancreas from the cysteamine-treated rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.3.E443

Inhibitory effect of rat amylin on the insulin responses to glucose and arginine in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.3.E443

Dose response characteristics for the hyperglycemic, hyperlactemic, hypotensive and hypocalcemic actions of amylin and calcitonin gene-related peptide-I (CGRP alpha) in the fasted, anaesthetized rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.3.E443

The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.3.E443

10.1152/AJPENDO.2001.280.3.E443

21 January 2018

Identifiers

DOI

0 references

1 reference